WASHINGTON, DC, January 7, 2015 — The Alliance for Regenerative Medicine (ARM), the international organization representing the regenerative medicine and advanced therapies industries, today announced its fifth annual State of the Industry Briefing will take place on Monday, January 12, 2015 in San Francisco.
The briefing will serve as a top-level gathering for key stakeholders in the advanced therapies sector, including business executives, investors, patient advocates and academic leaders, and will detail recent advances and provide an industry outlook for the coming year. The program will also include a discussion of expected clinical, regulatory and commercial inflection points for advanced therapies in 2015, as well as an in-depth conversation between leading CEOs on focal points for product development and commercialization including dosage, delivery methods and data read-outs.
Introduction & Industry Update
Edward Lanphier, President and CEO, Sangamo BioSciences; Chairman, Alliance for Regenerative Medicine
Gene Therapy & Genome Editing: Defining the Clinical & Commercial Requirements for Success
Katrine Bosley, CEO, Editas Medicine
Thomas Chalberg, Ph.D., Founder and CEO, Avalanche Biotechnologies
Steven Paul, M.D., CEO, Voyager Therapeutics
Joshua Schimmer, M.D., Managing Director and Senior Research Analyst, Piper Jaffray (moderator)
Jeffrey Walsh, COO, bluebird bio
Sue Washer, President and CEO, AGTC
Krisztina Zsebo, Ph.D., CEO, Celladon
Dose, Delivery, Data: Understanding the Three D’s of Advanced Therapy Drug Development
Tony Fiorino, M.D., Ph.D., CEO, BrainStorm Cell Therapeutics
Adam Gridley, President and CEO, Histogenics
Paul Laikind, Ph.D., President and CEO, ViaCyte
C. Randal Mills, Ph.D., President and CEO, California Institute for Regenerative Medicine (CIRM) (moderator)
Robert Willenbucher, M.D., Head, Janssen Cell Therapy and Head, Janssen Incubator, Janssen R&D
Paul Wotton, Ph.D., President and CEO, Ocata Therapeutics
“The past year saw our industry reach many major milestones, attracting substantial financial interest and bringing numerous revolutionary technologies and life-saving advances significantly closer to patients,” said Edward Lanphier, president and CEO of Sangamo BioSciences and chairman of ARM. “In the coming year, we look forward to sustaining this momentum in this maturing and incredibly dynamic industry.”
The briefing will take place at the Parc 55 Wyndham in San Francisco from 8:00 a.m. to 9:50 a.m. The event is free and open to the public; however, registration is required. The complete agenda and information on how to register is available online at http://alliancerm.org/event/regenerative-medicine-state-industry-briefing.
This briefing is held in conjunction with the Biotech Showcase™ 2015 investor conference, organized by EBD Group and Demy Colton. Attendance at this briefing is separate from registering to attend the Biotech Showcase™ 2015 conference, which requires paid registration. For full details on Biotech Showcase™ 2015, please visit the website: http://www.ebdgroup.com/bts/index.php.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.